A-201 Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study.

Authors :: Scarisbrick, J.
Arumainathan, A.
Cowan, R.
DeSimone, J.
Esler, C.
Geskin, L.J.
Goldaniga, M.
Violetti, S. Alberti
Mheidly, K.
Morsia, E.
Muniesa, C.
Musiek, A.
Nassi, L.
Pagano, L.
Pileri, A.
Pujol, R.M.
Quint, K.
Rozati, S.
Sandilands, K.
Shinohara, M.
Source :: European Journal of Cancer. 2024 Supplement 2, Vol. 211, pN.PAG-N.PAG. 1p.
Publication Year :: 2024

Subjects :: *THERAPEUTIC use of monoclonal antibodies
*MYCOSIS fungoides
*SEZARY syndrome
*CONFERENCES & conventions
*QUALITY of life
*SYMPTOMS

Full Text Access

Tools